• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

两种新型半合成脂糖肽对生物膜和生长后期稳定期细胞具有活性。

Two Novel Semisynthetic Lipoglycopeptides Active against Biofilms and Cells in Late Stationary Growth Phase.

作者信息

Vimberg Vladimir, Zieglerova Leona, Mazumdar Aninda, Szűcs Zsolt, Borbás Aniko, Herczegh Pál, Novotna Gabriela Balikova

机构信息

Institute of Microbiology, Czech Academy of Sciences, Průmyslova 595, 25250 Vestec, Czech Republic.

Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem Tér 1, H-4032 Debrecen, Hungary.

出版信息

Pharmaceuticals (Basel). 2021 Nov 19;14(11):1182. doi: 10.3390/ph14111182.

DOI:10.3390/ph14111182
PMID:34832964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8619453/
Abstract

The increase in antibiotic resistance among Gram-positive bacteria underscores the urgent need to develop new antibiotics. New antibiotics should target actively growing susceptible bacteria that are resistant to clinically accepted antibiotics including bacteria that are not growing or are protected in a biofilm environment. In this paper, we compare the in vitro activities of two new semisynthetic glycopeptide antibiotics, MA79 and ERJ390, with two clinically used glycopeptide antibiotics-vancomycin and teicoplanin. The new antibiotics effectively killed not only exponentially growing cells of , but also cells in the stationary growth phase and biofilm.

摘要

革兰氏阳性菌抗生素耐药性的增加凸显了开发新型抗生素的迫切需求。新型抗生素应针对对临床认可的抗生素具有耐药性的活跃生长的敏感细菌，包括不生长或在生物膜环境中受到保护的细菌。在本文中，我们比较了两种新型半合成糖肽抗生素MA79和ERJ390与两种临床使用的糖肽抗生素——万古霉素和替考拉宁的体外活性。这两种新型抗生素不仅能有效杀死处于指数生长期的细胞，还能杀死稳定生长期的细胞和生物膜中的细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/2795d16609af/pharmaceuticals-14-01182-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/b64268fc1609/pharmaceuticals-14-01182-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/c5024a90b08e/pharmaceuticals-14-01182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/1a2d4c4b6081/pharmaceuticals-14-01182-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/9cdf361cfa23/pharmaceuticals-14-01182-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/7990af9baace/pharmaceuticals-14-01182-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/5b3a67424739/pharmaceuticals-14-01182-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/a4f86bbc599f/pharmaceuticals-14-01182-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/d2429d0edbfc/pharmaceuticals-14-01182-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/2795d16609af/pharmaceuticals-14-01182-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/b64268fc1609/pharmaceuticals-14-01182-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/c5024a90b08e/pharmaceuticals-14-01182-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/1a2d4c4b6081/pharmaceuticals-14-01182-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/9cdf361cfa23/pharmaceuticals-14-01182-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/7990af9baace/pharmaceuticals-14-01182-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/5b3a67424739/pharmaceuticals-14-01182-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/a4f86bbc599f/pharmaceuticals-14-01182-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/d2429d0edbfc/pharmaceuticals-14-01182-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d4e7/8619453/2795d16609af/pharmaceuticals-14-01182-g009.jpg

相似文献

1
Two Novel Semisynthetic Lipoglycopeptides Active against Biofilms and Cells in Late Stationary Growth Phase.两种新型半合成脂糖肽对生物膜和生长后期稳定期细胞具有活性。
Pharmaceuticals (Basel). 2021 Nov 19;14(11):1182. doi: 10.3390/ph14111182.
2
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
3
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.奥利万星在体外可杀死处于稳定期和形成生物膜的金黄色葡萄球菌细胞。
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
4
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.生长阶段和pH值对新型糖肽类药物奥利万星（LY333328）体外抗金黄色葡萄球菌和粪肠球菌活性的影响。
J Antimicrob Chemother. 2002 Jul;50(1):19-24. doi: 10.1093/jac/dkf058.
5
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.糖肽类抗生素的比较综述：奥他万古霉素、达巴万星和替拉万星。
Pharmacotherapy. 2010 Jan;30(1):80-94. doi: 10.1592/phco.30.1.80.
6
Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm.基于在已建立生物膜中的活性评估对耐甲氧西林金黄色葡萄球菌有效的抗生素
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5688-94. doi: 10.1128/AAC.01251-16. Print 2016 Oct.
7
Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.与万古霉素和替考拉宁相比，糖肽类抗生素LY333328的体外活性评估。
J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273.
8
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素，对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
9
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.新型糖肽类抗生素：达巴万星、奥他万星和替拉万星的比较综述。
Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000.
10
New semisynthetic teicoplanin derivatives have comparable in vitro activity to that of oritavancin against clinical isolates of VRE.新型半合成替考拉宁衍生物对临床分离的 VRE 的体外活性与奥他万星相当。
J Antibiot (Tokyo). 2019 Jul;72(7):524-534. doi: 10.1038/s41429-019-0164-1. Epub 2019 Mar 15.

引用本文的文献

1
Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2021-2022.基质辅助激光解吸/电离质谱法分析碳水化合物和糖缀合物：2021 - 2022年最新进展
Mass Spectrom Rev. 2025 May-Jun;44(3):213-453. doi: 10.1002/mas.21873. Epub 2024 Jun 24.

本文引用的文献

1
VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to and Cells.VanZ降低脂糖肽类抗生素与[具体细胞类型1]和[具体细胞类型2]细胞的结合。
Front Microbiol. 2020 Apr 3;11:566. doi: 10.3389/fmicb.2020.00566. eCollection 2020.
2
Vancomycin resistant infections: A review of case updating and clinical features.耐万古霉素感染：病例更新与临床特征综述
J Adv Res. 2019 Oct 12;21:169-176. doi: 10.1016/j.jare.2019.10.005. eCollection 2020 Jan.
3
Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria.
万古霉素的复兴：克服多重耐药菌抗生素耐药性的方法。
Can J Microbiol. 2020 Jan;66(1):11-16. doi: 10.1139/cjm-2019-0309. Epub 2019 Sep 23.
4
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.耐甲氧西林金黄色葡萄球菌：基础与临床研究概述。
Nat Rev Microbiol. 2019 Apr;17(4):203-218. doi: 10.1038/s41579-018-0147-4.
5
Biofilm Formation of Staphylococcus aureus under Food Heat Processing Conditions: First Report on CML Production within Biofilm.金黄色葡萄球菌在食品热加工条件下的生物膜形成：生物膜内 CML 产生的首次报告。
Sci Rep. 2019 Feb 4;9(1):1312. doi: 10.1038/s41598-018-35558-2.
6
Fluorescence assay to predict activity of the glycopeptide antibiotics.荧光分析法预测糖肽类抗生素的活性。
J Antibiot (Tokyo). 2019 Feb;72(2):114-117. doi: 10.1038/s41429-018-0120-5. Epub 2018 Nov 30.
7
Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.疏水性替考拉宁假糖衍生物作为新型抗流感病毒药物的构效关系研究。
Eur J Med Chem. 2018 Sep 5;157:1017-1030. doi: 10.1016/j.ejmech.2018.08.058. Epub 2018 Aug 22.
8
Developments in Glycopeptide Antibiotics.糖肽类抗生素的发展
ACS Infect Dis. 2018 May 11;4(5):715-735. doi: 10.1021/acsinfecdis.7b00258. Epub 2018 Feb 19.
9
Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.在使用含达巴万星和万古霉素的方案治疗耐甲氧西林金黄色葡萄球菌（MRSA）中心静脉相关血流感染后，出现了达巴万星不敏感、万古霉素中介性金黄色葡萄球菌（VISA）。
Clin Microbiol Infect. 2018 Apr;24(4):429.e1-429.e5. doi: 10.1016/j.cmi.2017.07.028. Epub 2017 Aug 3.
10
Microbial Biofilms and Chronic Wounds.微生物生物膜与慢性伤口
Microorganisms. 2017 Mar 7;5(1):9. doi: 10.3390/microorganisms5010009.